Karyopharm Therapeutics Inc.
KPTI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $62 | $52 | $135 | $190 |
| Short-Term Investments | $46 | $139 | $143 | $38 |
| Receivables | $31 | $27 | $47 | $22 |
| Inventory | $5 | $3 | $4 | $4 |
| Other Curr. Assets | $12 | $12 | $21 | $20 |
| Total Curr. Assets | $156 | $234 | $350 | $276 |
| Property Plant & Equip (Net) | $6 | $5 | $7 | $10 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $2 | $1 | $20 |
| Total NC Assets | $8 | $7 | $8 | $30 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $164 | $240 | $358 | $305 |
| Liabilities | – | – | – | – |
| Payables | $5 | $3 | $3 | $2 |
| Short-Term Debt | $25 | $3 | $3 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $62 | $63 | $60 | $70 |
| Total Curr. Liab. | $92 | $69 | $66 | $74 |
| LT Debt | $170 | $174 | $176 | $178 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $89 | $133 | $133 | $133 |
| Total NC Liab. | $258 | $307 | $309 | $311 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $7 | $6 | $9 | $11 |
| Total Liabilities | $350 | $377 | $375 | $385 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,563 | -$1,487 | -$1,344 | -$1,179 |
| AOCI | -$0 | -$0 | -$1 | $0 |
| Other Equity | $1,378 | $1,351 | $1,328 | $1,099 |
| Total Equity | -$186 | -$136 | -$17 | -$80 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $164 | $240 | $358 | $305 |
| Net Debt | $132 | $125 | $44 | -$10 |